This case highlights the thrombogenic role of aβ2GPI IgA in seronegative APS and demonstrates the potential efficacy of antiplatelet therapy, a strategy not prioritized in current APS guidelines favoring anticoagulation therapy, in reversing arterial occlusion and preventing recurrence in non-criteria APS. Here, CD79A is linked to autoimmune polyendocrinopathy.